The injectable borofalan (10B), developed by CNNC Headway—a subsidiary of China Isotope & Radiation Corporation (CIRC) under the China National Nuclear Corporation (CNNC)—has officially entered Phase I clinical trials
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Dr. Bandichhor brings nearly two decades of experience from Dr. Reddy's Laboratories
Subscribe To Our Newsletter & Stay Updated
